How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,340 results for

fluoroquinolones

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Pandemic uropathogenic fluoroquinolone-resistant Escherichia coli have enhanced ability to persist in the gut and cause bacteriuria in healthy women. (Abstract)

Pandemic uropathogenic fluoroquinolone-resistant Escherichia coli have enhanced ability to persist in the gut and cause bacteriuria in healthy women. We report that fluoroquinolone resistant Escherichia coli are found in feces of 8.8% healthy adult women, with most bacteria belonging to pandemic multi-drug resistant ST131-H30R or ST1193 clonal groups. Moreover, these highly uropathogenic clonal groups demonstrate an especially prolonged gut persistence and high rate of bacteriuria without

2019 Clinical Infectious Diseases

42. Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone. Full Text available with Trip Pro

Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone. The purpose of this study was to measure the electrocardiographic (ECG) effects of WCK 2349 (the L-alanine ester prodrug of levonadifloxacin) at a supratherapeutic oral dose of 2,600 mg. A total of 48 healthy volunteers were randomized to treatment with placebo, WCK 2349, or oral moxifloxacin, 400 mg, in a crossover-designed thorough QT study. A supratherapeutic mean maximum levonadifloxacin

2019 Clinical and translational science Controlled trial quality: uncertain

43. Differences in clinical manifestations, antimicrobial susceptibility patterns and mutations of fluoroquinolone target genes between <i>Chryseobacterium gleum</i> and <i>Chryseobacterium indologenes</i>. Full Text available with Trip Pro

Differences in clinical manifestations, antimicrobial susceptibility patterns and mutations of fluoroquinolone target genes between Chryseobacterium gleum and Chryseobacterium indologenes. Chryseobacterium infections are uncommon, and previous studies have revealed that C. gleum is frequently misidentified as C. indologenes We aimed to explore the differences in clinical manifestations and antimicrobial susceptibility patterns between C. gleum and C. indologenes The database (...) of susceptibility to piperacillin, piperacillin-tazobactam, ceftazidime, tigecycline, and levofloxacin. Alterations in DNA gyrase subunit A were identified to be associated with fluoroquinolone resistance in C. indologenes No non-synonymous substitutions were observed in the QRDRs of C. gleum Differences in epidemiology, clinical manifestations, and antimicrobial susceptibility patterns exist between C. gleum and C. indologenes Additional investigations are needed to explore the significance

2019 Antimicrobial Agents and Chemotherapy

44. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m Full Text available with Trip Pro

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment compliance, and high costs (...) . The development of new efficient regimens with shorter treatment durations for MDR-TB will solve these issues and improve treatment outcomes.This study is a phase II/III, multicenter, randomized, open-label clinical trial of non-inferiority design comparing a new regimen to the World Health Organization-endorsed conventional regimen for fluoroquinolone-sensitive MDR-TB. The control arm uses a conventional treatment regimen with second-line drugs including injectables for 20-24 months. The investigational arm

2019 Trials

45. Assessing Fluoroquinolone-associated Aortic Aneurysm and Dissection: Data Mining of the Public Version of the FDA Adverse Event Reporting System. (Abstract)

Assessing Fluoroquinolone-associated Aortic Aneurysm and Dissection: Data Mining of the Public Version of the FDA Adverse Event Reporting System. A recent large epidemiological study found fluoroquinolone use is associated with an increased risk of aortic aneurysm or dissection. We aimed to examine fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) associated aortic aneurysm or dissection through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS (...) reports, all three fluoroquinolones are associated with aortic aneurysm, and levofloxacin is associated with aortic dissection. Risk of aortic aneurysm is higher than aortic dissection. Oral administration of fluoroquinolones is more likely to produce these adverse events.The results obtained herein are consistent with clinical observations, suggesting the necessity for further clinical research on aortic aneurysm and dissection associated with fluoroquinolones. This article is protected by copyright

2019 International journal of clinical practice

46. Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Full Text available with Trip Pro

Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Fluoroquinolones are the pillar of multi-drug resistant tuberculosis (MDR-TB) treatment, with either moxifloxacin, levofloxacin or gatifloxacin being prescribed to MDR-TB patients. Recently, several clinical trials of 'universal' drug regimens, aiming to treat drug susceptible and resistant TB, have included a fluoroquinolone. In the absence of clinical data (...) comparing their side-by-side efficacy in controlled MDR-TB trials, a pharmacological rationale is needed to guide the selection of the most efficacious fluoroquinolone. The present studies were designed to test the hypothesis that fluoroquinolone concentrations (pharmacokinetics) and activity (pharmacodynamics) at the site of infection are better predictors of efficacy than plasma concentrations and potency measured in standard growth inhibition assays, and to determine whether one

2019 Antimicrobial Agents and Chemotherapy

47. Correction: Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy. Full Text available with Trip Pro

Correction: Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy. The original version of this article contained an error in the name of author Alfredo Mena Lora. This has now been corrected.

2019 Prostate cancer and prostatic diseases

48. Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital. Full Text available with Trip Pro

Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital. Mycoplasma hominis is considered among the causes of urogenital infections and shows increasing resistance to fluoroquinolones. However, data regarding the fluoroquinolone resistance mechanism of M. hominis in Southwest China are limited. This study aimed to investigate gene mutations of quinolone resistance-determining regions (QRDRs) of M. hominis isolated from (...) clinical urogenital samples in a Chinese hospital.Strains of M. hominis were identified by 16S rRNA gene sequencing. The minimal inhibitory concentrations (MICs) of fluoroquinolones were determined by the broth microdilution method, following CLSI guidelines. PCR was used to amplify the QRDRs of the genes gyrA, gyrB, parC and parE. Positive products were sequenced, and gene mutations and amino acid substitutions were analysed by DNAMAN software and BLAST.The resistance rates of M. hominis

2019 Journal of Medical Microbiology

49. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. Full Text available with Trip Pro

Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. Guidelines recommend macrolides and fluoroquinolones in patients hospitalized with community-acquired pneumonia (CAP), but their use has been associated with cardiac events. We quantified associations between macrolide and fluoroquinolone use and cardiac events in patients hospitalized with CAP in non-ICU wards.This was a post-hoc (...) analysis of a cluster-randomized trial as a cohort study; including patients with a working diagnosis of CAP admitted to non-ICU wards without a cardiac event on admission. We calculated cause-specific hazard ratio's (HR's) for effects of time-dependent macrolide and fluoroquinolone exposure as compared to beta-lactam monotherapy on cardiac events, defined as new or worsening heart failure, arrhythmia, or myocardial ischemia during hospitalization.Cardiac events occurred in 146 (6.9%) of 2107 patients

2019 BMC Infectious Diseases Controlled trial quality: uncertain

50. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study (Abstract)

Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study To quantify the risk of secondary pseudotumor cerebri syndrome (PTCS) with fluoroquinolones.A case-control study of people 15-60 years of age from the LifeLink Database (QuintilesIMS, Parsippany, NJ) was conducted. Cases had the first ICD-9-CM code for benign intracranial hypertension (BIH) as well as having received a procedure code for an MRI or CT scan and a lumbar puncture within 15 days (...) or 30 days of the BIH code. For each case, 10 controls were selected using density-based sampling. Current users of fluoroquinolones received a prescription within 15 days or 30 days of the date of the diagnosis. For the sensitivity analysis, risk periods for 30 and 60 days were also examined. Adjusted rate ratios (RRs) were computed from a conditional logistic regression model.From a cohort of 6,110,723 people, there were 339 cases of PTCS and 3,390 corresponding controls. In the primary analysis

2017 EvidenceUpdates

51. Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection. Full Text available with Trip Pro

Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection. Fluoroquinolones are group A drugs in tuberculosis guidelines. We aim to compare the culture conversion between new- (levofloxacin and moxifloxacin) and old-generation (ciprofloxacin and ofloxacin) fluoroquinolones, develop pharmacokinetic models, and calculate target attainment for levofloxacin and moxifloxacin. We included three U.S. tuberculosis (...) centers. Patients admitted between 1984 and 2015, infected with drug-resistant tuberculosis, and received fluoroquinolones for ≥28 days were included. Demographics, sputum cultures and susceptibility, treatment regimens, and serum concentrations were collected. A time-to-event analysis was conducted, and Cox proportional hazards model was used to compare the time to culture conversion. Using additional data from ongoing studies, pharmacokinetic modelling and Monte Carlo simulations were performed

2019 Antimicrobial Agents and Chemotherapy

52. Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Full Text available with Trip Pro

Profile of a Novel Anionic Fluoroquinolone-Delafloxacin. Fluoroquinolones have been in clinical use for over 50 years with significant efficacy. However, increasing resistance and emergence of some marked adverse events have limited their usage. The most recently approved class member, delafloxacin, is the only available anionic (non-zwitterionic) fluoroquinolone. Its unique molecular structure provides improved in vitro activity against most Gram-positive pathogens, including quinolone

2019 Clinical Infectious Diseases

53. Fluoroquinolone use and serious arrhythmias: A Nationwide Case-Crossover Study. (Abstract)

Fluoroquinolone use and serious arrhythmias: A Nationwide Case-Crossover Study. Fluoroquinolones have been associated with life-threatening ventricular arrhythmias and even sudden cardiac death. We aimed to assess the temporal relationship of fluoroquinolone use and serious arrhythmias via a case-crossover analysis of a large cohort of serious arrhythmias patients.In a national administrative database, we compare the distributions of fluoroquinolone exposure for the same patient across a 30-day (...) period before the serious arrhythmia event and 5 randomly selected 30-day periods before the serious arrhythmia event. Odds ratios (ORs) and 95% Confidence Intervals (CIs) were estimated using conditional logistic regression analysis.From a total of 2 million participants, 7657 patients with serious arrhythmias were identified. Use of fluoroquinolones within the 30-day period before the event was significantly associated with increased risk for serious arrhythmia (OR: 3.03, 95% CI: 2.48, 3.71

2019 Resuscitation

54. Fluoroquinolone resistance in carbapenem-resistant Elizabethkingia anophelis: phenotypic and genotypic characteristics of clinical isolates with topoisomerase mutations and comparative genomic analysis. Full Text available with Trip Pro

Fluoroquinolone resistance in carbapenem-resistant Elizabethkingia anophelis: phenotypic and genotypic characteristics of clinical isolates with topoisomerase mutations and comparative genomic analysis. MDR Elizabethkingia anophelis strains are implicated in an increasing number of healthcare-associated infections worldwide, including a recent cluster of E. anophelis infections in the Midwestern USA associated with significant morbidity and mortality. However, there is minimal information (...) on the antimicrobial susceptibilities of E. anophelis strains or their antimicrobial resistance to carbapenems and fluoroquinolones.Our aim was to examine the susceptibilities and genetic profiles of clinical isolates of E. anophelis from our hospital, characterize their carbapenemase genes and production of MBLs, and determine the mechanism of fluoroquinolone resistance.A total of 115 non-duplicated isolates of E. anophelis were examined. MICs of antimicrobial agents were determined using the Sensititre 96-well

2019 Journal of Antimicrobial Chemotherapy

55. Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007-2014. Full Text available with Trip Pro

Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007-2014. Antimicrobial resistance in Mycoplasma genitalium is rising globally with resultant clinical treatment failure. We investigated the prevalence of mutations in the macrolide and fluoroquinolone resistance-determining regions of M. genitalium in Johannesburg, South Africa, and ascertained their association with HIV serostatus.Stored M. genitalium positive specimens (...) were detected in any of the specimens analysed. QRDR mutations with known M. genitalium-associated fluoroquinolone resistance were not detected in gyrA, however, one specimen (0.4%) contained a D87Y amino acid alteration in parC, which has been linked to fluoroquinolone treatment failure. The most common parC amino acid change detected, of unknown clinical significance, was P62S (18.8%). We found no significant association between QRDR mutations in M. genitalium and HIV-infection.Ongoing

2019 BMC Infectious Diseases

56. The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study. Full Text available with Trip Pro

The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study. Fluoroquinolones increase the risk of Clostridioides difficile infection and antibiotic resistance. Hospitals often use pre-prescription approval or prospective audit and feedback to target fluoroquinolone prescribing. Whether these strategies impact aggregate fluoroquinolone use is unknown.This study is a 48-hospital, retrospective cohort of general-care, medical (...) patients hospitalized with pneumonia or positive urine culture between December 2015-September 2017. Hospitals were surveyed on their use of pre-prescription approval and/or prospective audit and feedback to target fluoroquinolone prescribing during hospitalization (fluoroquinolone stewardship). After controlling for hospital clustering and patient factors, aggregate (inpatient and post-discharge) fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) exposure was compared between hospitals

2019 Clinical Infectious Diseases

57. Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis

Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

58. Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials

Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

59. Re: Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients with Elevated Serum Prostate-Specific Antigen is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. (Abstract)

Re: Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients with Elevated Serum Prostate-Specific Antigen is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. 29539905 2018 12 21 2018 12 21 1527-3792 197 5 2017 05 The Journal of urology J. Urol. Re: Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients with Elevated Serum Prostate-Specific Antigen is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. 1276 S0022-5347(17)30279-3 10.1016/j.juro (...) .2017.02.058 Schaeffer Edward M EM eng Journal Article Comment 2017 02 21 United States J Urol 0376374 0022-5347 0 Anti-Bacterial Agents 0 Anti-Infective Agents 0 Fluoroquinolones EC 3.4.21.77 Prostate-Specific Antigen AIM IM Urology. 2016 Apr;90:32-7 26802800 Anti-Bacterial Agents Anti-Infective Agents Fluoroquinolones Humans Male Prostate-Specific Antigen 2018 3 16 6 0 2018 3 16 6 0 2018 12 24 6 0 ppublish 29539905 S0022-5347(17)30279-3 10.1016/j.juro.2017.02.058

2018 The Journal of urology Controlled trial quality: uncertain

60. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. (Abstract)

Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. The emergence of antimicrobial resistance threatens current clinical practice across a range of infection types. Delafloxacin, a non-zwitterionic fluoroquinolone recently approved by the US FDA for the treatment of acute bacterial skin and skin structure infections, has been developed to address some of these challenges. Uniquely delafloxacin has increased intracellular penetration and enhanced (...) antibacterial activity under acidic conditions, an environment seen in many infection sites including abscesses. Delafloxacin is active against a wide range of Gram-positive and -negative species including methicillin-resistant Staphylococcus aureus and many fluoroquinolone-resistant strains. Additionally, according to preclinical and clinical trial data, well-known adverse events related to fluoroquinolone class do not appear to occur with this new molecule. Delafloxacin has been studied in acute bacterial

2018 Future microbiology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>